Search
Research
Immunisation and pregnancy - who, what, when and why?Recommending vaccination to pregnant women is important as evidence shows they are more likely to get vaccinated if their healthcare provider advises it
Research
Effectiveness of seasonal trivalent influenza vaccination against hospital-attended acute respiratory infections in pregnant womenInfluenza vaccination during pregnancy was associated with significantly fewer hospital attendances for ARI in pregnant women
Research
COVID-19 vaccination in children and adolescents aged 5 years and older undergoing treatment for cancer and non-malignant haematological conditions: Australian and New Zealand Children’s Haematology/Oncology Group consensus statementThe Australian Technical Advisory Group on Immunisation and New Zealand Ministry of Health recommend all children aged ≥ 5 years receive either of the two mRNA COVID-19 vaccines: Comirnaty (Pfizer), available in both Australia and New Zealand, or Spikevax (Moderna), available in Australia only. Both vaccines are efficacious and safe in the general population, including children. Children and adolescents undergoing treatment for cancer and immunosuppressive therapy for non-malignant haematological conditions are particularly vulnerable, with an increased risk of severe or fatal COVID-19.
Research
Pertussis Disease and Antenatal Vaccine Effectiveness in Australian ChildrenPopulation-level studies of severe pertussis extending beyond infancy are sparse, and none in the context of antenatal vaccination. We compared hospitalized pertussis cases from birth to 15 years of age before and after introduction of antenatal immunization.
Research
Using provider-parent strategies to improve influenza vaccination in children and adolescents with special risk medical conditions: a randomised controlled trial protocolInfluenza immunisation is a highly cost-effective public health intervention. Despite a comprehensive National Immunisation Program, influenza vaccination in children and adolescents with special risk medical conditions (SRMCs) is suboptimal. Flutext-4U is an innovative, multi-component strategy targeting paediatric hospitals, general practice and parents of children and adolescents with SRMC.
Research
Post tuberculosis disabilityKefyalew Alene BSc, MPH, PhD Head, Geospatial and Tuberculosis 0404705064 Kefyalew.alene@thekids.org.au Honorary Research Fellow Dr Kefyalew Alene
Research
Spatiotemporal patterns of drug susceptible and drug resistant tuberculosis in Hunan Province, ChinaInvestigators: Kefyalew Alene, Archie Clements External collaborators: Kerri Viney, Dr Darren J Gray (Australian National University) Zuhui Xu (
Research
Prevalence of and risk factors for human rhinovirus infection in healthy aboriginal and non-aboriginal western australian childrenHuman rhinovirus (HRV) species C (HRV-C) have been associated with frequent and severe acute lower respiratory infections and asthma in hospitalized children.
Research
Reduction in disparity for pneumonia hospitalisations between Australian indigenous and non-Indigenous childrenIn the 1990s pneumonia hospitalisation rates in Western Australia (WA) were 13 times higher in Indigenous children than in non-Indigenous children...
Research
Hospitalisation for bronchiolitis in infants is more common after elective caesarean deliveryThe authors previously reported an increased risk of hospitalisation for acute lower respiratory infection up to age 2 years in children delivered by...